Phase I and II clinical trials of fresolimumab (a monoclonal anti-TGFβ antibody) have been conducted in renal cell carcinoma, melanoma, mesothelioma, and breast cancer [43,44,45]. The gene discussed is TGFB1; the disease is breast carcinoma.